Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-324552

ABSTRACT

Background: With the widespread outbreak of novel coronavirus diseases 2019(COVID-19), more and more death cases were reported, however, limited data are available for the patients who died. We aimed to explore the clinial characteristics of deaths with COVID-19 pneumonia Methods: : We abstracted and analyzed epidemiological, demographic, clinical, and laboratory data from 83 death cases with COVID-19 pneumonia in East hospital of Wuhan university Renmin hospital,between January 26, 2020, and February 28, 2020. Results: : Of the 83 deaths, none was the medical staff. The mean age was 71.8 years (SD 13.2;range, 34-97 years) and 53(63.9%) were male. The median from onset to admission was 10 days (IQR 7-14: range, 2-43 days), to death was 17days (IQR 14-21: range, 6-54 days). Most deaths (66[80%]) had underlying comorbid diseases, the most of which was hypertension [47(57%)]. The main initial symptoms of these 83 deaths were shortness of breath(98.8%), fever(94%) and myalgia or fatigue(90.4%). Laboratory analyses showed the lymphocytopenia in 69(83%) deaths, hypoalbuminemia in 77(93%) deaths, the elevation of lactate dehydrogenase in 79(95%) deaths, procalcitonin in 69(83%) deaths and C-reactive protein in 79(95%) deaths. All 83 patients received antiviral treatment, 81(97.6%) deaths received antibiotic therapy, and 54(65.1%) deaths received glucocorticoid therapy and 20(24.1%) patients received invasive mechanical ventilation. Conclusion: Most of the deaths with COVID-19 pneumonia were elderly patients with underlying comorbid diseases, especially those over 70 years of age. The time of death was mostly 15-21 days after the onset of the disease. More care should be given to the elderly in the further prevention and control strategies of COVID-19.

2.
J Med Virol ; 93(4): 2365-2373, 2021 04.
Article in English | MEDLINE | ID: covidwho-1217386

ABSTRACT

Coronavirus disease 2019 (COVID-19) is a newly emerging infectious disease. Our understanding of the clinical characteristics of liver damage and the relationship with disease severity in COVID-19 is still limited. To investigate the serum hepatic enzyme activities in different phenotypes of COVID-19 patients, evaluate their relationship with the illness severity and analyze the correlation of glycyrrhizin treatment and abnormal liver enzyme activities, one hundred and forty-seven patients with COVID-19 were enrolled in a retrospective study that investigated hepatic dysfunction. Liver alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactic dehydrogenase (LDH), Y-glutamyl transferase (GGT), superoxide dismutase (SOD), and alkaline phosphatase (ALP) were analyzed in these patients. Patients with diammonium glycyrrhizinate (DG) treatment were further investigated. Of the 147 patients, 56 (38.1%) had abnormal ALT activity and 80 (54.4%) had abnormal AST activity. The peak of abnormal hepatic enzyme activities occurred at 3 to 6 days after on admission. Serum AST and LDH levels were elevated, while the SOD level was decreased in severe and critical patients, compared with mild cases. DG treatment may alleviate the abnormal liver enzyme activities in non-critical COVID-19 patients. Abnormal liver functions may be observed in patients with COVID-19, and were associated with SARS-CoV-2-induced acute liver damage. Glycyrrhizin treatment may be an effective therapeutic approach for the outcome of abnormal hepatic enzyme activities in severe COVID-19 cases. Serum hepatic enzyme tests may reflect the illness severity and should be monitored.


Subject(s)
COVID-19/enzymology , Liver/enzymology , Adult , Aged , Aged, 80 and over , Alanine Transaminase/blood , Alkaline Phosphatase/blood , Aspartate Aminotransferases/blood , COVID-19/blood , COVID-19/metabolism , Female , Humans , Liver/metabolism , Liver Function Tests , Male , Middle Aged , Phenotype , Retrospective Studies , SARS-CoV-2 , Severity of Illness Index , Superoxide Dismutase/blood , Young Adult
3.
SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-4065

ABSTRACT

A review. The first known outbreak of Corona Virus Disease 2019(COVID-19) is in wuhan, china in Dec. 2019,the new type of acute infectious diseases which quickly spread across the country. Author thought starting from the "internal" is the general treatment method. The tongue coating performance is an important basis to judge Disease changes. qi deficiency and dry cough should be as main symptoms in clin. diagnosis and treatment. The fundamental pathogenesis is deficiency of qi deficiency and insufficiency of the body fluid, so strengthening the body resistance to eliminate pathogenic factors with adherence to treatment of strengthen qi and nourishing Yin is the total therapeutic principles. According to the theory of wuyun and liuqi, the plague occurrence is a response to the abnormal climate, but this year will not appear abnormal climate, which is conducive to the control of the epidemic.

4.
SSRN; 2020.
Preprint | SSRN | ID: ppcovidwho-611

ABSTRACT

Background: With the widespread outbreak of (novel coronavirus disease 2019 ) COVID-19, more and more death cases were reported, however, limited data are avail

5.
BMC Infect Dis ; 20(1): 695, 2020 Sep 22.
Article in English | MEDLINE | ID: covidwho-781451

ABSTRACT

BACKGROUND: With the widespread outbreak of novel coronavirus diseases 2019(COVID-19), more and more death cases were reported, however, limited data are available for the patients who died. We aimed to explore the clinical characteristics of deaths with COVID-19 pneumonia. METHODS: We abstracted and analyzed epidemiological, demographic, clinical, and laboratory data from 83 death cases with COVID-19 pneumonia in East Hospital of Wuhan University Renmin Hospital, between January 26, 2020, and February 28, 2020. RESULTS: Of the 83 deaths, none was the medical staff. The mean age was 71.8 years (SD 13.2; range, 34-97 years) and 53(63.9%) were male. The median from onset to admission was 10 days (IQR 7-14: range, 2-43 days), to death was 17 days (IQR 14-21: range, 6-54 days). Most deaths (66[80%]) had underlying comorbid diseases, the most of which was hypertension [47(57%)]. The main initial symptoms of these 83 deaths were shortness of breath(98.8%), fever(94%), and myalgia or fatigue(90.4%). Laboratory analyses showed the lymphocytopenia in 69(83%) deaths, hypoalbuminemia in 77(93%) deaths, the elevation of lactate dehydrogenase in 79(95%) deaths, procalcitonin in 69(83%) deaths and C-reactive protein in 79(95%) deaths. All 83 patients received antiviral treatment, 81(97.6%) deaths received antibiotic therapy, 54(65.1%) deaths received glucocorticoid therapy, and 20(24.1%) patients received invasive mechanical ventilation. CONCLUSION: Most of the deaths with COVID-19 pneumonia were elderly patients with underlying comorbid diseases, especially those over 70 years of age. The time of death after the onset of the disease was mostly 15-21 days. More care should be given to the elderly in further prevention and control strategies of COVID-19.


Subject(s)
Coronavirus Infections/mortality , Pneumonia, Viral/mortality , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Betacoronavirus , C-Reactive Protein/analysis , COVID-19 , China/epidemiology , Coronavirus Infections/therapy , Fatigue , Female , Fever/virology , Glucocorticoids/therapeutic use , Hospitalization , Humans , Hypertension/complications , L-Lactate Dehydrogenase/blood , Male , Middle Aged , Pandemics , Pneumonia, Viral/therapy , Procalcitonin/blood , Respiration, Artificial , Retrospective Studies , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL